Blebbishields, the emergency program for cancer stem cells: Sphere formation and tumorigenesis after apoptosis

Cell Death and Differentiation

Volumn 20, Issue 3, 2013, Pages 382-395

  Jinesh, G G ^a   Choi, W ^a   Shah, J B ^a   Lee, E K ^a   Willis, D L ^a   Kamat, A M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

apoptosis; blebbishields; cancer stem cells; caspase; p70S6K; VEGFR2

Indexed keywords

AMILORIDE; CASPASE; CISPLATIN; ESOMEPRAZOLE; FILIPIN; HEPARIN; LITHIUM CHLORIDE; S6 KINASE; TUNICAMYCIN; VASCULOTROPIN RECEPTOR 2;

ACIDITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLEBBISHIELD; CANCER CELL CULTURE; CANCER STEM CELL; CARCINOGENESIS; CELL FUSION; CELL SURVIVAL; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; COISOGENIC STRAIN; CONTROLLED STUDY; GLYCOSYLATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTICHOLESTEREMIC AGENTS; APOPTOSIS; CASPASE INHIBITORS; CASPASES; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; GLYCOSYLATION; HUMANS; HYDROGEN-ION CONCENTRATION; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; PROTON PUMP INHIBITORS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84873717960     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2012.140     Document Type: Article

References (43)

1. Knoepfler PS. Why myc? An unexpected ingredient in the stem cell cocktail. Cell Stem Cell 2008; 2: 18-21.
2. Li F, He Z, Shen J, Huang Q, Li W, Liu X et al. Apoptotic caspases regulate induction of iPSCs from human fibroblasts. Cell Stem Cell 2010; 7: 508-520.
3. Kim J, Woo AJ, Chu J, Snow JW, Fujiwara Y, Kim CG et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 2010; 143: 313-324.
4. Klonisch T, Wiechec E, Hombach-Klonisch S, Ande SR, Wesselborg S, Schulze-Osthoff K et al. Cancer stem cell markers in common cancers-therapeutic implications. Trends Mol Med 2008; 14: 450-460.
5. Golebiewska A, Brons NH, Bjerkvig R, Niclou SP. Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell 2011; 8: 136-147.
6. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-284.
7. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010; 140: 62-73.
8. Maugeri-Sacca M, Vigneri P, De Maria R. Cancer stem cells and chemosensitivity. Clin Cancer Res 2011; 17: 4942-4947.
9. Cho RW, Clarke MF. Recent advances in cancer stem cells. Curr Opin Genet Dev 2008; 18: 48-53.
10. Nunez R, Sancho-Martinez SM, Novoa JM, Lopez-Hernandez FJ. Apoptotic volume decrease as a geometric determinant for cell dismantling into apoptotic bodies. Cell Death Differ 2010; 17: 1665-1671.
11. Hanahan D,Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
12. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-768.
13. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000; 406: 532-535.
14. Gleason CE, Ning Y, Cominski TP, Gupta R, Kaestner KH, Pintar JE et al. Role of insulinlike growth factor-binding protein 5 (IGFBP5) in organismal and pancreatic beta-cell growth. Mol Endocrinol 2010; 24: 178-192.
15. Zhang HH, Lipovsky AI, Dibble CC, Sahin M, Manning BD. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell 2006; 24: 185-197.
16. Armstrong JL, Bonavaud SM, Toole BJ, Yeaman SJ. Regulation of glycogen synthesis by amino acids in cultured human muscle cells. J Biol Chem 2001; 276: 952-956.
17. Dhar R, Persaud SD, Mireles JR, Basu A. Proteolytic cleavage of p70 ribosomal S6 kinase by caspase-3 during DNA damage-induced apoptosis. Biochemistry 2009; 48: 1474-1480.
18. Constantinou C, Elia A, Clemens MJ. Activation of p53 stimulates proteasome-dependent truncation of eIF4E-binding protein 1 (4E-BP1). Biol Cell 2008; 100: 279-289.
19. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 2004; 10: 55-63.
20. Laurenti E, Varnum-Finney B, Wilson A, Ferrero I, Blanco-Bose WE, Ehninger A et al. Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. Cell Stem Cell 2008; 3: 611-624.
21. Yamamoto T, Yoneda K, Ueta E, Doi S, Osaki T. Enhanced apoptosis of squamous cell carcinoma cells by interleukin-2-activated cytotoxic lymphocytes combined with radiation and anticancer drugs. Eur J Cancer 2000; 36: 2007-2017.
22. Andrade F, Roy S, Nicholson D, Thornberry N, Rosen A, Casciola-Rosen L. Granzyme B directly and efficiently cleaves several downstream caspase substrates: implications for CTL-induced apoptosis. Immunity 1998; 8: 451-460.
23. Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J 1999; 18: 5242-5251.
24. Prescher JA, Bertozzi CR. Chemical technologies for probing glycans. Cell 2006; 126: 851-854.
25. Veugelers K, Motyka B, Goping IS, Shostak I, Sawchuk T, Bleackley RC. Granulemediated killing by granzyme B and perforin requires a mannose 6-phosphate receptor and is augmented by cell surface heparan sulfate. Mol Biol Cell 2006; 17: 623-633.
26. Chernomordik LV, Leikina E, Frolov V, Bronk P, Zimmerberg J. An early stage of membrane fusion mediated by the low pH conformation of influenza hemagglutinin depends upon membrane lipids. J Cell Biol 1997; 136: 81-93.
27. Parolini I, Federici C, Raggi C, Lugini L, Palleschi S, De Milito A et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem 2009; 284: 34211-34222.
28. Fais S, De Milito A, You H, Qin W. Targeting vacuolar H-ATPases as a new strategy against cancer. Cancer Res 2007; 67: 10627-10630.
29. Hjelmeland AB, Wu Q, Heddleston JM, Choudhary GS, MacSwords J, Lathia JD et al. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ 2011; 18: 829-840.
30. Fais S. Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism. J Intern Med 2010; 267: 515-525.
31. Raaijmakers MH, Scadden DT. Divided within: heterogeneity within adult stem cell pools. Cell 2008; 135: 1006-1008.
32. Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002; 417: 954-958.
33. Takahashi T, Shibuya M. The 230kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene 1997; 14: 2079-2089.
34. You WK, Kasman I, Hu-Lowe DD, McDonald DM. Ricinus communis agglutinin I leads to rapid down-regulation of VEGFR-2 and endothelial cell apoptosis in tumor blood vessels. Am J Pathol 2010; 176: 1927-1940.
35. Meyer RD, Srinivasan S, Singh AJ, Mahoney JE, Gharahassanlou KR, Rahimi N. PEST motif serine and tyrosine phosphorylation controls vascular endothelial growth factor receptor 2 stability and downregulation. Mol Cell Biol 2011; 31: 2010-2025.
36. Hamerlik P, Lathia JD, Rasmussen R, Wu Q, Bartkova J, Lee M et al. Autocrine VEGFVEGFR2- Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med 2012; 209: 507-520.
37. Banerjee A, Lang JY, Hung MC, Sengupta K, Banerjee SK, Baksi K et al. Unfolded protein response is required in nu/nu mice microvasculature for treating breast tumor with tunicamycin. J Biol Chem 2011; 286: 29127-29138.
38. Dougher AM, Wasserstrom H, Torley L, Shridaran L, Westdock P, Hileman RE et al. Identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor. Growth Factors 1997; 14: 257-268.
39. Xu L, Fukumura D, Jain RK. Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF. J Biol Chem 2002; 277: 11368-11374.
40. Taraboletti G, D'Ascenzo S, Giusti I, Marchetti D, Borsotti P, Millimaggi D et al. Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. Neoplasia 2006; 8: 96-103.
41. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genomewide expression patterns. Proc Nat Acad Sci USA 1998; 95: 14863-14868.
42. Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R et al. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 2004; 3: 279-290.
43. Kamat AM, Tharakan ST, Sung B, Aggarwal BB. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. Cancer Res 2009; 69: 8958-8966.